Urology
Volume 57, Issue 4, Supplement 1 , Pages 77-80 , April 2001

Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer

  • Raymond C Bergan

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School and the Robert H. Lurie Cancer Center of Northwestern University, Chicago, Illinois, USA (RCB)
    • Corresponding Author InformationReprint requests: Raymond C. Bergan, MD, Olson 8524, 710 North Fairbanks, Chicago, IL 60611-3008
    • ,
  • Doyle H Waggle

      Affiliations

    • Protein Technologies International, St. Louis, Missouri, USA (DHW)
    • ,
  • Stephen K Carter

      Affiliations

    • Sugen, Inc., San Francisco, California, USA (SKC)
    • ,
  • Ivan Horak

      Affiliations

    • Pharmacia, Peapack, New Jersey, USA (IH)
    • ,
  • William Slichenmyer

      Affiliations

    • Parke-Davis, Ann Arbor, Michigan, USA (WS)
    • ,
  • Michael Meyers

      Affiliations

    • Aventis Inc., Parsippany, New Jersey, USA (MM)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0090-4295(00)00946-8

Urology
Volume 57, Issue 4, Supplement 1 , Pages 77-80 , April 2001

Article Tools

* Image Usage & Resolution